DOI:

A rare publication with a unique message: the joint guidelines on the management of valvular heart disease by the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery

Davide Capodanno

This February issue is special because it contains only one article, but what an article! In fact, we are co-publishing the guidelines of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery on the management of valvular heart disease. We also have a timely editorial by Catherine Otto, first author of the joint American College of Cardiology and American Heart Association guidelines on the same topic, which illustrates the main similarities and differences of the two documents that come from either side of the Atlantic. On this occasion, I would like to thank the European Society of Cardiology for allowing the co-publication of this document in our Journal and the European Association of Percutaneous Cardiovascular Interventions, with its Board and Presidential trio, for their support in carrying out this request. I was part of the Task Force that drafted these guidelines, so I will refrain from personal comments on the contents. Social media, as always, has amplified the discussion around guidelines presented at the European Society of Cardiology Congress – which is positive for their broad dissemination and uptake. I have a feeling that the key principles of this document have been well-received, without divisions that go beyond the normal and fair scientific debate. After all, these are guidelines produced by the European Society of Cardiology together with the European Association for Cardio-Thoracic Surgery, which represents the most exemplary illustration of the Heart Team concept that is interwoven transversally throughout the document. Unsurprisingly, and in general, the guidelines methodology is debated. Catherine Otto, in her Editorial, mentions some aspects that can be improved upon with a view to creating an ever-better process. What I have learned as an author, however, is that the process is more solid than what I, myself, could have expected as a reader (and of course, you can decide to trust me or not). The process is intended to foster debate, representing different opinions and the involvement not only of the multidisciplinary components of the task force, but of countless reviewers as well. Contrary to more conspiratorial views, from what I can testify from my own personal experience, this is not a process that allows overly extreme or potentially biased opinions to take the lead. A methodological review is undertaken and strict rounds of votes with prespecified criteria are required before the several rounds of review process begin. I have seen some who are reluctant to reconcile their positions converge after long discussions in the interest of science and community service. I have no counterevidence to support this, but I would like to think that different people, using the same methodology and moving from the same extremes, would reach the same recommendations. That said, guidelines exist to inform readers about best practices regarding the treatment of certain conditions. It is up to us to read and interpret them for what they are: a practical guide that does not replace decisions based on science, experience and conscience, all in the best interests of our patients.

Supplementary data

To read the full content of this article, please download the PDF.

Volume 17 Number 14
Feb 4, 2022
Volume 17 Number 14
View full issue

Suggested by Cory

Editorial

10.4244/EIJ-D-26-00648 Jul 20, 2026
When less is no longer more: very early aspirin discontinuation after ACS
Piccolo R and Vitale A
free

Editorial

10.4244/EIJ-E-26-00010 Jul 20, 2026
Aspirin withdrawal after primary PCI for STEMI: timing matters
Paradies V and Mancini G
free

Editorial

10.4244/EIJ-D-26-00715 Jul 20, 2026
Endotype-guided management of ANOCA: are we ready?
Montone R
free

Original Research

10.4244/EIJ-D-26-00148 Jul 20, 2026
Endotype-guided medical therapy and symptom response in ANOCA
Farina J et al

Research Correspondence

10.4244/EIJ-D-25-01215 Jul 20, 2026
Prevalence of vasomotor dysfunction in patients with residual or recurrent angina after percutaneous coronary intervention
Crooijmans C et al

Flashlight

10.4244/EIJ-D-25-00731 Jul 20, 2026
Collapse of a new-generation magnesium scaffold
Bastante T et al
Trending articles
83.3

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
48.15

State-of-the-Art

10.4244/EIJ-D-25-00874 Jun 1, 2026
TAVI and coronary interventions: indications, technical considerations, and clinical scenarios
Aquino Bruno H et al
free
45.65

State-of-the-Art

10.4244/EIJ-D-25-01346 May 4, 2026
Slow flow and no reflow after percutaneous coronary intervention
Brugaletta S et al
free
38.2

State-of-the-Art

10.4244/EIJ-D-24-00195 Apr 7, 2025
Percutaneous coronary intervention for calcified and resistant lesions
Pesarini G et al
free
33.9

Original Research

10.4244/EIJ-D-26-00032 May 15, 2026
Glucocorticoids to reduce permanent pacemaker implantation after TAVI: the GLUCO-TAVI randomised trial
Fuertes-Kenneally L et al
29.2

Original Research

10.4244/EIJ-D-25-01370 May 21, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
29.2

Original Research

10.4244/EIJ-D-25-01370 Jun 1, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
21.9

Research Correspondence

10.4244/EIJ-D-26-00271 May 20, 2026
Outcomes of percutaneous mechanical aspiration in left-sided infective endocarditis
Lugo-Fagundo NS et al
21.9

Research Correspondence

10.4244/EIJ-D-26-00271 Jul 6, 2026
Outcomes of percutaneous mechanical aspiration in left-sided infective endocarditis
Lugo-Fagundo NS et al
X

PCR
Impact factor: 9.2
2025 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2026)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved